Guardant Health, Inc. (NASDAQ: GH) has disclosed that it has submitted a lawsuit against Natera, Inc for false advertisement, biased opposition, and illegal trade practices. The firm has spread the wrong statement about its products and the performance of a new oncology test, Guardant Reveal of Guardant Health.

Guardant Health has requested the federal court in San Francisco, California for an order which stops Natera from making wrong or deceptive declarations and needs Natera to take remedial actions. The launch of Guardant Reveal signifies an important medical revolution for the 1.5 million early-stage colorectal cancer survivors in the U.S.

The Guardant Reveal test tracking circulating tumor DNA (ctDNA) from a simple blood draw and is performed after surgery to recognize sufferers with residual disease who may benefit most from adjuvant therapy and surveillance. The test can also distinguish repetition months earlier than current standard-of-care methods, such as carcinoembryonic antigen tests or imaging.3-8 Guardant Health’s method for ctDNA discovery is greatly diverse from Natera’s Signatera assay, which involves a tissue biopsy.

The criticism stated that Natera is deceiving healthcare providers about the performance of the Guardant Reveal test by indicating the test is false and/or callous and inferior to Signatera. As a direct result, colorectal cancer sufferers are missing chances for minimal residual disease (MRD) detection and relapse monitoring and the employee benefits of driven cure decisions.